融捷健康(300247) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥176,333,541.57, representing an increase of 11.42% compared to ¥158,259,198.06 in the same period last year[5]. - Net profit attributable to shareholders was ¥20,825,834.91, marking an 86.12% increase from ¥11,189,537.80 year-on-year[5]. - Basic earnings per share rose to ¥0.0259, an increase of 86.33% compared to ¥0.0139 in the same period last year[5]. - Total operating revenue for Q1 2024 was CNY 176,333,541.57, an increase of 11.5% compared to CNY 158,259,198.06 in Q1 2023[27]. - Net profit for Q1 2024 reached CNY 28,219,984.12, representing a growth of 54.2% from CNY 18,327,304.00 in the same period last year[28]. - The company's operating profit increased to CNY 36,780,586.93, up by 45.7% from CNY 25,233,202.51 in Q1 2023[28]. - The company reported a total comprehensive income of CNY 25,504,271.67, an increase of 51.9% from CNY 16,808,961.24 in the same quarter last year[28]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 14.14% to ¥53,537,093.95, up from ¥46,906,552.61 in the previous year[5]. - Cash inflow from operating activities increased by 24.29%, attributed to higher sales collections and recovery of prior receivables[16]. - The company's cash and cash equivalents increased by 87.9% to ¥104,731,800, driven by increased sales collections and the redemption of financial products[19]. - The cash inflow from investment activities was CNY 120,353,364.99, significantly higher than CNY 35,749,988.36 in Q1 2023[30]. - The total cash and cash equivalents at the end of the period reached 223,882,753.18, up from 117,286,775.92 in the previous period[31]. - The net increase in cash and cash equivalents for the quarter was 104,731,771.65, compared to 48,986,574.33 in the same quarter last year[31]. - The cash outflow from financing activities totaled 3,210,017.12, resulting in a net cash flow from financing activities of -3,210,017.12[31]. - The impact of exchange rate changes on cash and cash equivalents was 664,760.29, contrasting with -1,288,723.24 in the previous period[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,250,318,370.98, a 2.35% increase from ¥1,221,559,067.16 at the end of the previous year[5]. - The total current assets reached CNY 849,978,927.57, up from CNY 818,023,730.17, indicating an increase of approximately 3.5%[23]. - The company's inventory decreased to CNY 131,316,384.57 from CNY 143,918,712.57, showing a decline of about 8.8%[23]. - The total liabilities of the company were CNY 152,107,103.35, compared to CNY 148,852,071.21 at the beginning of the period, marking an increase of approximately 1.7%[24]. - The company's accounts receivable decreased to CNY 28,774,610.77 from CNY 41,568,724.53, reflecting a decline of about 30.8%[23]. - The non-current assets totaled CNY 400,339,443.41, slightly down from CNY 403,535,336.99, indicating a decrease of about 0.5%[24]. - The company's equity remained stable at CNY 804,040,313.00, unchanged from the previous period[24]. Shareholding and Ownership - The company reported a total of 116,912,302 shares held by Rongjie Investment Holding Group, representing 14.54% of the total shares[20]. - The company has no significant changes in the shareholding structure of the top 10 shareholders, indicating stability in ownership[20]. Research and Development - Research and development expenses for the quarter were CNY 2,369,330.52, which is a 14.7% increase from CNY 2,065,738.44 in the previous year[27]. Audit Status - The company has not undergone an audit for the first quarter report[32].